Email ID : 
Password : 
Forgot Your Password ? 

Only Report Titles
Titles & Keywords
NOTE: Site best viewed with Internet Explorer
  LUNG CANCER THERAPEUTICS
A Global Strategic Business Report

This report analyzes the worldwide markets (Annual Revenues) for Lung Cancer Therapeutics in Annual Revenues in Millions of US$. The US market for Non-Small Cell Lung Cancer treatment is further analyzed by: Chemotherapy Drugs, and Targeted Drugs. The report provides separate comprehensive analytics for the US, Europe and Rest of World. Annual forecasts are provided for each region for the period 2005 through 2015. The report profiles 191 companies including many key and niche players worldwide such as AstraZeneca PLC., Bristol-Myers Squibb Co., Eli Lilly & Co., F. Hoffmann-La Roche Ltd., Genentech, Inc., GlaxoSmithKline Plc., Novartis Pharmaceuticals Corporation, OSI Pharmaceuticals, Inc., Sanofi-Aventis, AbGenomics International Inc., ImClone Systems, Inc., Pfizer, Inc., Merck Serono International S.A., Merck & Co. Ltd., Telik, Inc., and Woomera Therapeutics, Inc. Market data and analytics are derived from primary and secondary research. Company profiles are mostly extracted from URL research and reported select online sources.

CODE:    MCP-1873  PAGES:    842
PRICE:    $3950  DATE:       July 2009
COMPANIES:  191  MARKET DATA TABLES:   277
Due to the proprietary nature, our previews are offered only to manufacturers, top-tier management consultants, investment banks, and investment research groups.

 TABLE OF CONTENTS  
  LUNG CANCER THERAPEUTICS (Complete Report) Pages : 842   | $3950
I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS3$100
   Study Reliability and Reporting Limitations.....I-1  
   Disclaimers.....I-2
Data Interpretation & Reporting Level.....I-2
  
   Quantitative Techniques & Analytics.....I-3
Product Definitions and Scope of Study.....I-3
Chemotherapy Drugs.....I-3
Targeted Drugs.....I-3
  
II. EXECUTIVE SUMMARY50$2250
  1. MARKET OVERVIEW.....II-14 $400  
   Lung Cancer Therapeutics – Driven by Next Generation Drugs.....II-1
New Therapies Drive NSCLC Market.....II-1
1$100
   Market Value of Taxanes to Decrease by 2015.....II-2
Lung Cancer – The Killer Disease.....II-2
1$100
   Lung Cancer – A Quick Glance at Global Statistics.....II-31$100
   Asia Heading for Possible Lung Cancer Epidemic.....II-4
Table 1: Global Incidence of Lung Cancer (2008): Percentage Share Breakdown by Region (includes corresponding Graph/Chart).....II-4
1$300
  2. LUNG CANCER – AN INSIGHT.....II-55 $500  
   Lungs – Critical for Oxygen Supply.....II-5
Lung Cancer – An Introduction.....II-5
Common Symptoms of Lung Cancer.....II-5
1$100
   Types of Lung Cancer.....II-6
Non-Small Cell Lung Cancer.....II-6
NSCLC – At a Glance.....II-6
Small Cell Lung Cancer.....II-6
1$100
   Risk Factors for Lung Cancer.....II-7
Female Smokers at Higher Risk of Developing Lung Cancer.....II-7
Lung Cancer Diagnostics.....II-7
1$100
   Lung Cancer Staging.....II-81$100
   Staging for Non-Small Cell Lung Cancer.....II-9
Staging for Small Cell Lung Cancer.....II-9
1$100
  3. LUNG CANCER TREATMENT MODALITIES.....II-102 $200  
   Surgery .....II-10
Radiation Therapy.....II-10
Chemotherapy.....II-10
Combination Therapy.....II-10
1$100
   Photodynamic Therapy.....II-11
Vaccines.....II-11
Common Treatment Modalities for SCLC and NSCLC Lung Cancers.....II-11
Pain Management.....II-11
1$100
  4. INTRODUCTION TO LUNG CANCER THERAPEUTICS.....II-127 $500  
   Chemotherapy.....II-12
Drug Administration.....II-12
Overview of Chemotherapy Regimens and Drugs.....II-12
1$100
   Side Effects of Chemotherapy.....II-13
Targeted Therapy.....II-13
Chemotherapy Drugs for SCLC Treatment.....II-13
1$100
   Chemotherapy Drugs for NSCLC Treatment.....II-14
Major Chemotherapy Drugs.....II-14
Select Chemotherapy Drugs Used in the Treatment of Lung Cancer by Brand and Generic
  Name.....II-14
1$100
   Overview of Select Chemotherapeutic Drugs.....II-15
Alimta.....II-15
Carboplatin and Cisplatin.....II-15
1$100
   Docetaxel.....II-16
Paclitaxel.....II-16
1$100
   Xyotax.....II-17
Gemcitabine.....II-17
Gefitinib.....II-17
1$100
   Irinotecan.....II-18
Vinorelbine (Navelbine®).....II-18
1$100
  5. PRODUCT DEVELOPMENT IN NSCLC THERAPEUTICS.....II-196 $400  
   R&D Focus in NSCLC Treatment.....II-19
Drug Development Process – Growth Opportunities & Challenges.....II-19
1$100
   Product Pipeline for NSCLC Treatment.....II-20
Product Pipeline for NSCLC Treatment.....II-20
1$100
   Select (Ongoing/Completed) Clinical Trials for NSCLC Treatment.....II-211$100
   Companies Focus on Molecular Targeted Therapies.....II-22
Molecular Targeted Therapies – Overview of Select Product Candidates.....II-22
Aflibercept (VEGF-Trap) – Sanofi Aventis/ Regeneron.....II-22
BIBW 2992 – Boehringer Ingelheim.....II-22
Erbitux (cetuximab) - ImClone/Merck Serono/Bristol- Myers Squibb.....II-22
1$100
   Nexavar (sorafenib) - Bayer Schering.....II-23
Recentin (cediranib) – AstraZeneca.....II-23
Sutent (sunitinib) – Pfizer.....II-23
Zactima (vandetanib) – AstraZeneca.....II-23
Zolinza (vorinostat) – Merck & Co.....II-23
1$100
   Pipeline for Cytotoxic Therapy – Overview of Select Products.....II-24
Abraxane (albumin-bound paclitaxel) - Abraxis.....II-24
Glutoxim (NOV-002) - Novelos.....II-24
Javlor (vinflunine) – Pierre Fabre.....II-24
Lipoplatin (liposomal cisplatin) – Regulon.....II-24
Xyotax (paclitaxel polyglumex) - Cell Therapeutics/ Novartis.....II-24
1$100
  6. PRODUCT APPROVALS/INNOVATIONS/ LAUNCHES.....II-254 $400  
   Intas Biopharmaceuticals to Introduce Gefitinib in India.....II-25
Celgene Receives FDA Fast Track Product Designation for Amrubicin.....II-25
EMEA Approves ALIMTA for First-Line Therapy of Advanced NSCLC.....II-25
Celgene’s Cancer Drug Receives Orphan Drug Status from European Commission.....II-25
1$100
   Alimta Receives FDA Approval.....II-26
Roche Receives Approval from European Authorities for Avastin.....II-26
OSI Pharmaceuticals Introduces Tarceva in Japan.....II-26
Shanghai Medipharm Introduces TNT Antibody for Treating Lung Cancer.....II-26
Natco Pharma Unveils an Injectible Drug for Lung Cancer, Pemnat.....II-26
1$100
   Roche Scientific Introduces Tarceva in the Indian Market.....II-27
GlaxoSmithKline’s HYCAMTIN® Receives Marketing Approval from EC.....II-27
Genzyme Launches New Genetic Mutation Test to Aid Lung Cancer Treatment.....II-27
1$100
   UT Southwestern Medical Center Researchers Discover New Anti-Cancer Drug.....II-28
Agennix's Talactoferrin Alfa Program Obtains Fast Track Designation from FDA.....II-28
Novelos Therapeutics’ NOV-002 Receives Fast Track Designation from FDA.....II-28
1$100
  7. RESEARCH & CLINICAL TRIALS.....II-298 $600  
   Novartis Commences Phase III Clinical Trial of ASA404.....II-29
Results of BR.21 Trials.....II-29
Genentech Announces Results of Phase III BETA Lung Trial.....II-29
Results of SATURN Clinical Trial.....II-29
1$100
   Results of Zactima’s Clinical Trials.....II-30
Results of Erbitux’s Phase III Trials.....II-30
Results of Roche’s AVAiL Clinical Trial.....II-30
1$100
   GlaxoSmithKline Conducts Phase III Clinical Trial of Lung Cancer Vaccine.....II-31
FASgen Announces Research Results of FAS093.....II-31
The Cuban Regulatory Agency Registers a New Therapeutic Lung Cancer Vaccine.....II-31
1$100
   Gemin X Commences Clinical Trials of GX15-070.....II-32
Antisoma and Biomira Announce Clinical Trial Results of Lung Cancer Drugs.....II-32
1$100
   OSI Pharmaceuticals Commences Phase III Clinical Trials of Tarceva®.....II-33
Northwest Gets FDA Clearance to Conduct Clinical Trials for Lung Cancer
  Vaccine.....II-33
University of Kentucky Conducts Clinical Trials on Lung Cancer Vaccine.....II-33
1$100
   Poniard Enrolls in Phase II Small Cell Lung Cancer Clinical Trials of
  Picoplatin.....II-34
Sunesis Pharmaceuticals Starts Phase II Clinical Trials of SNS-595.....II-34
1$100
   Ligand Pharmaceuticals Tables Clinical Results of Targretin®.....II-35
Bayer and Onyx Start Phase III Trial of Nexavar®.....II-35
Abraxis Announces Clinical Results of ABRAXANE®.....II-35
Introgen Conducts Phase II Clinical Trials of INGN 225.....II-35
1$100
   YM BioSciences Commences Clinical Trial of Nimotuzumab.....II-36
1$100
  8. RECENT INDUSTRY ACTIVITY.....II-378 $500  
   Merck Agrees to Merge with Shering-Plough.....II-37
Abbott Molecular Signs Agreement with Genentech, OSI and Roche.....II-37
IMUC Acquires Monoclonal Antibody Technology from MDC.....II-37
Quest PharmaTech Enters into Collaboration with BC Cancer Agency.....II-37
1$100
   Daiichi Sankyo Acquires U3 Pharma.....II-38
MacroGenics Takes Over Raven Biotechnologies.....II-38
Roche Acquires Piramed.....II-38
1$100
   Bristol-Myers Squibb Acquires Kosan Biosciences.....II-39
Point Therapeutics and DARA Biosciences Ink Merger Agreement.....II-39
Celgene Acquires Pharmion.....II-39
Pfizer to Takeover Serenex.....II-39
ATS Acquires Majority Stake in GANYMED Pharmaceuticals.....II-39
1$100
   NCCN, AstraZeneca and Abraxis Enter into Collaboration.....II-40
Eli Lilly Agrees to Take Over ImClone Systems.....II-40
CytRx Takes Over Innovive Pharmaceuticals.....II-40
1$100
   Abbott Extends Discovery Partnership with Caprion.....II-41
Bristol-Myers and ImClone to Expand the Clinical Development Program for
  ERBITUX.....II-41
1$100
   Biomoda and New Mexico Tech Enter into a Collaborative Agreement.....II-42
Binex Inks Sponsored Research Agreement with MaxCyte.....II-42
Simcere Pharmaceutical Acquires Master Luck.....II-42
Dako Enters into Collaboration with OSI, Roche, and Genentech.....II-42
1$100
   Biomira and Merck Sign Revised Supply and Collaboration Agreements.....II-43
ImClone Systems Terminates Development Agreement with UCB.....II-43
Astellas Pharma’s US Subsidiary Acquires Agensys.....II-43
1$100
   Antisoma Enters into an Agreement with Novartis.....II-44
Pharmacyclics Files NDA for Xcytrin® Injection.....II-44
1$100
  9. FOCUS ON SELECT GLOBAL PLAYERS.....II-454 $400  
   AstraZeneca PLC (UK).....II-45
Bristol-Myers Squibb Co. (US).....II-45
Eli Lilly & Co. (US).....II-45
F. Hoffmann-La Roche Ltd (Switzerland).....II-45
1$100
   Genentech, Inc. (US).....II-46
GlaxoSmithKline Plc (UK).....II-46
Novartis Pharmaceuticals Corporation (US).....II-46
OSI Pharmaceuticals, Inc. (US).....II-46
Sanofi-Aventis (France).....II-46
1$100
   Companies with Pipeline Drugs.....II-47
AbGenomics International Inc. (US).....II-47
ImClone Systems, Inc. (US).....II-47
Pfizer, Inc. (US).....II-47
Merck Serono International S.A. (Switzerland).....II-47
Merck & Co. Ltd. (US).....II-47
1$100
   Telik, Inc. (US).....II-48
Woomera Therapeutics, Inc. (US).....II-48
1$100
  10. GLOBAL MARKET PERSPECTIVE.....II-49   
   Table 2: World Recent Past, Current & Future Analysis for Non-Small Cell Lung Cancer Therapeutics Market by Geographic Region – US, Europe and Rest of World Independently Analyzed with Annual Revenues in US$ Million for Years 2005 through 2015 (includes corresponding Graph/Chart).....II-491$300
   Table 3: World 10-Year Perspective for Non-Small Cell Lung Cancer Therapeutics by Geographic Region – Percentage Breakdown of Annual Revenues for US, Europe and Rest of World Markets for Years 2006, 2009 & 2015 (includes corresponding Graph/Chart).....II-501$300
III. MARKET36$1950
  1. THE UNITED STATES.....III-116 $775  
   A. Market Analysis.....III-1
NSCLC Drug Market to Rise Sharply.....III-1
Lung Cancer Prevalence.....III-1
A Major Cause of Death among US Women.....III-1
1$75
   Statistics.....III-21$75
   Market Scenario.....III-3
FDA Places New Restrictions on Iressa.....III-3
Innovative Technology Enables Early Diagnosis of Lung Cancer.....III-3
Avastin to Emerge as the Preferred NSCLC Drug in the US.....III-3
1$75
   Product Approvals/Clinical Trials/Introductions/ Launches.....III-43$225
   Strategic Corporate Developments.....III-76$450
   Key Players.....III-133$225
   B. Market Analytics.....III-16
Table 4: US Recent Past, Current & Future Analysis for Non-Small Cell Lung Cancer Therapeutics by Segment – Chemotherapy Drugs and Targeted Drugs Markets Independently Analyzed with Annual Revenues in US$ Million for Years 2005 through 2015 (includes corresponding Graph/Chart).....III-16

Table 5: US 10-Year Perspective for Non-Small Cell Lung Cancer Therapeutics by Segment – Percentage Breakdown of Annual Revenues for Chemotherapy Drugs and Targeted Drugs Markets for Years 2006, 2009 & 2015.....III-16
1$150
  2. EUROPE.....III-174 $300  
   A. Market Analysis.....III-17
Lung Cancer Therapeutics Market to Witness Robust Growth.....III-17
Product Approvals.....III-17
2$150
   Clinical Trials.....III-19
B. Market Analytics.....III-19
Table 6: European Recent Past, Current & Future Analysis for Non-Small Cell Lung Cancer Therapeutics by Geographic Region – France, Germany, Italy, UK and Rest of Europe Independently Analyzed with Annual Revenues in US$ Million for Years 2005 through 2015 (includes corresponding Graph/Chart).....III-19
1$150
   Table 7: European 10-Year Perspective for Non-Small Cell Lung Cancer Therapeutics Market by Geographic Region – Percentage Breakdown of Annual Revenues for France, Germany, Italy, UK and Rest of Europe Markets for Years 2006, 2009 & 2015 (includes corresponding Graph/Chart).....III-20
1$150
  2a. FRANCE.....III-212 $150  
   A. Market Analysis.....III-21
Overview of Lung Cancer Market.....III-21
Key Player.....III-21
1$75
   B. Market Analytics.....III-22
Table 8: French Recent Past, Current & Future Analysis for Non-Small Cell Lung Cancer Therapeutics Market Analyzed with Annual Revenues in US$ Million for Years 2005 through 2015 (includes corresponding Graph/Chart).....III-22
1$150
  2b. GERMANY.....III-233 $225  
   A. Market Analysis.....III-23
Lung Cancer Scenario.....III-23
Chemotherapy Gains Preference.....III-23
1$75
   Strategic Corporate Developments.....III-241$75
   B. Market Analytics.....III-25
Table 9: German Recent Past, Current & Future Analysis for Non-Small Cell Lung Cancer Therapeutics Market Analyzed with Annual Revenues in US$ Million for Years 2005 through 2015 (includes corresponding Graph/Chart).....III-25
1$150
  2c. ITALY.....III-261 $150  
   A. Market Analysis.....III-26
Incidence in Women on Rise.....III-26
Treatment.....III-26
B. Market Analytics.....III-26
Table 10: Italian Recent Past, Current & Future Analysis for Non-Small Cell Lung Cancer Therapeutics Market Analyzed with Annual Revenues in US$ Million for Years 2005 through 2015 (includes corresponding Graph/Chart).....III-26
1$150
  2d. THE UNITED KINGDOM.....III-273 $225  
   A. Market Analysis.....III-27
British Women at Higher Risk.....III-27
Fast Facts.....III-27
Proposed Cancer Care Improvements Mulled by British Government.....III-27
1$75
   NICE Recommends Use of Erlotinib in NSCLC Treatment.....III-28
Strategic Corporate Developments.....III-28
1$75
   Key Players.....III-29
B. Market Analytics.....III-29
Table 11: UK Recent Past, Current & Future Analysis for Non-Small Cell Lung Cancer Therapeutics Market Analyzed with Annual Revenues in US$ Million for Years 2005 through 2015 (includes corresponding Graph/Chart).....III-29
1$150
  2e. REST OF EUROPE.....III-302 $150  
   A. Market Analysis.....III-30
Outlook.....III-30
Strategic Corporate Developments.....III-30
Key Player.....III-30
1$75
   B. Market Analytics.....III-31
Table 12: Rest of Europe Recent Past, Current & Future Analysis for Non-Small Cell Lung Cancer Therapeutics Market Analyzed with Annual Revenues in US$ Million for Years 2005 through 2015 (includes corresponding Graph/Chart).....III-31
1$150
  3. REST OF WORLD.....III-325 $275  
   A. Market Analysis.....III-32
Australia.....III-32
Fast Facts.....III-32
Brazil.....III-32
China.....III-32
Overview of NSCLC Drug Market.....III-32
1$75
   India.....III-33
Japan.....III-33
Product Launches.....III-33
2$150
   Strategic Corporate Development.....III-351$75
   B. Market Analytics.....III-36
Table 13: Rest of World Recent Past, Current & Future Analysis for Non-Small Cell Lung Cancer Therapeutics Market Analyzed with Annual Revenues in US$ Million for Years 2005 through 2015 (includes corresponding Graph/Chart).....III-36
1$150
IV. COMPETITIVE LANDSCAPE 739$995
  
Total Companies Profiled: 191 (including Divisions/Subsidiaries - 200)

Region/Country                 Players


The United States               104
Canada                            9
Japan                             6
Europe                           23
     France                       4
     Germany                      7
     The United Kingdom           5
     Italy                        2
     Rest of Europe               5
Asia-Pacific (Excluding Japan)   58
Click here to request a full table of contents and more details on this project.		  
 
 
Due to the proprietary nature, our previews are offered only to manufacturers, top-tier management consultants, investment banks, and investment research groups.

© Copyrights 2010, Global Industry Analysts, Inc., USA.